TY - JOUR
T1 - The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation
AU - Tryphonopoulos, Panagiotis
AU - Tzakis, Andreas G.
AU - Weppler, Debbie
AU - Garcia-Morales, Rolando
AU - Kato, Tomoaki
AU - Madariaga, Juan R.
AU - Levi, David M.
AU - Nishida, Seigo
AU - Moon, Jang
AU - Selvaggi, Gennaro
AU - Regev, Arie
AU - Nery, Caio
AU - Bejarano, Pablo
AU - Khaled, Amr
AU - Kleiner, Gary
AU - Esquenazi, Violet
AU - Miller, Joshua
AU - Ruiz, Philip
AU - Ricordi, Camillo
PY - 2005/3
Y1 - 2005/3
N2 - We investigated the role of donor bone marrow cell (DBMC) infusions in immunosuppression withdrawal in adult liver transplantation. Patients enrolled were at least 3 years post-transplantation, with stable graft function. Forty-five (study group: G1) received DBMC, and 59 (control group: G2) did not. Immunosuppression was reduced by one third upon enrollment, by another third the second year of the study and was completely withdrawn the third year. Patient and graft survival were similar between the two groups. Although rejection episodes were significantly less in G1 the first 2 years of the study (35% vs. 57%, p = 0.016), there was no significant difference overall (74% vs. 81%, p = 0.14). Until February 2004, 20 patients, 10 in each group, were immunosuppression free for 1-3 years. Approximately 20% of long-term survivors of liver transplantation can successfully discontinue their immunosuppression. DBMC infusions, do not increase this likelihood.
AB - We investigated the role of donor bone marrow cell (DBMC) infusions in immunosuppression withdrawal in adult liver transplantation. Patients enrolled were at least 3 years post-transplantation, with stable graft function. Forty-five (study group: G1) received DBMC, and 59 (control group: G2) did not. Immunosuppression was reduced by one third upon enrollment, by another third the second year of the study and was completely withdrawn the third year. Patient and graft survival were similar between the two groups. Although rejection episodes were significantly less in G1 the first 2 years of the study (35% vs. 57%, p = 0.016), there was no significant difference overall (74% vs. 81%, p = 0.14). Until February 2004, 20 patients, 10 in each group, were immunosuppression free for 1-3 years. Approximately 20% of long-term survivors of liver transplantation can successfully discontinue their immunosuppression. DBMC infusions, do not increase this likelihood.
KW - Donor bone narrow infusion
KW - Immunosuppression withdrawal
KW - Liver transplantation
KW - Tolerance
UR - http://www.scopus.com/inward/record.url?scp=20044361820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20044361820&partnerID=8YFLogxK
U2 - 10.1111/j.1600-6143.2004.00743.x
DO - 10.1111/j.1600-6143.2004.00743.x
M3 - Article
C2 - 15707417
AN - SCOPUS:20044361820
SN - 1600-6135
VL - 5
SP - 608
EP - 613
JO - American Journal of Transplantation
JF - American Journal of Transplantation
IS - 3
ER -